Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3)

The NCI PDXNet Consortium

doi:10.1038/s41467-021-27678-7

Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3)

The NCI PDXNet Consortium

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Abstract

In this Article the Competing interests statement inadvertently omitted a statement for M.T.L. and L.E.D. The competing financial interests for M.T.L. should have read: ‘M.T.L. is a founder and limited partner in StemMed Ltd. and a manager in StemMed Holdings, its general partner. He is a founder and equity stakeholder in Tvardi Theraeutics Inc. Some PDXs are exclusively licensed to StemMed Ltd. resulting in royalty income to M.T.L.’. The competing financial interests for L.E.D. should have read, ‘L.E.D. is a compensated employee of StemMed Ltd’. The PDF and HTML versions of the Article have been corrected.

Original language	English (US)
Article number	294
Journal	Nature communications
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41467-021-27678-7
State	Published - Dec 2022

All Science Journal Classification (ASJC) codes

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

Access to Document

10.1038/s41467-021-27678-7

Fingerprint

Dive into the research topics of 'Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3)'. Together they form a unique fingerprint.

Cite this

@article{d061fbe1bbdd4175ac4d87eebf9be05c,

title = "Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3)",

abstract = "In this Article the Competing interests statement inadvertently omitted a statement for M.T.L. and L.E.D. The competing financial interests for M.T.L. should have read: {\textquoteleft}M.T.L. is a founder and limited partner in StemMed Ltd. and a manager in StemMed Holdings, its general partner. He is a founder and equity stakeholder in Tvardi Theraeutics Inc. Some PDXs are exclusively licensed to StemMed Ltd. resulting in royalty income to M.T.L.{\textquoteright}. The competing financial interests for L.E.D. should have read, {\textquoteleft}L.E.D. is a compensated employee of StemMed Ltd{\textquoteright}. The PDF and HTML versions of the Article have been corrected.",

author = "\{The NCI PDXNet Consortium\} and Hua Sun and Song Cao and Mashl, \{R. Jay\} and Mo, \{Chia Kuei\} and Simone Zaccaria and Wendl, \{Michael C.\} and Davies, \{Sherri R.\} and Bailey, \{Matthew H.\} and Primeau, \{Tina M.\} and Jeremy Hoog and Mudd, \{Jacqueline L.\} and Dean, \{Dennis A.\} and Rajesh Patidar and Li Chen and Wyczalkowski, \{Matthew A.\} and Jayasinghe, \{Reyka G.\} and Rodrigues, \{Fernanda Martins\} and Terekhanova, \{Nadezhda V.\} and Yize Li and Lim, \{Kian Huat\} and Andrea Wang-Gillam and \{Van Tine\}, \{Brian A.\} and Ma, \{Cynthia X.\} and Rebecca Aft and Fuh, \{Katherine C.\} and Schwarz, \{Julie K.\} and Zevallos, \{Jose P.\} and Puram, \{Sidharth V.\} and Dipersio, \{John F.\} and Julie Belmar and Jason Held and Jingqin Luo and \{Van Tine\}, \{Brian A.\} and Rose Tipton and Yige Wu and Lijun Yao and Zhou, \{Daniel Cui\} and Andrew Butterfield and Zhengtao Chu and Maihi Fujita and Yang, \{Chieh Hsiang\} and Emilio Cortes-Sanchez and Sandra Scherer and Ling Zhao and Tijana Borovski and Vicki Chin and John DiGiovanna and Christian Frech and Jeffrey Grover and Raphael, \{Benjamin J.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2022",

month = dec,

doi = "10.1038/s41467-021-27678-7",

language = "English (US)",

volume = "13",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3). / The NCI PDXNet Consortium.
In: Nature communications, Vol. 13, No. 1, 294, 12.2022.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Author Correction

T2 - Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3)

AU - The NCI PDXNet Consortium

AU - Sun, Hua

AU - Cao, Song

AU - Mashl, R. Jay

AU - Mo, Chia Kuei

AU - Zaccaria, Simone

AU - Wendl, Michael C.

AU - Davies, Sherri R.

AU - Bailey, Matthew H.

AU - Primeau, Tina M.

AU - Hoog, Jeremy

AU - Mudd, Jacqueline L.

AU - Dean, Dennis A.

AU - Patidar, Rajesh

AU - Chen, Li

AU - Wyczalkowski, Matthew A.

AU - Jayasinghe, Reyka G.

AU - Rodrigues, Fernanda Martins

AU - Terekhanova, Nadezhda V.

AU - Li, Yize

AU - Lim, Kian Huat

AU - Wang-Gillam, Andrea

AU - Van Tine, Brian A.

AU - Ma, Cynthia X.

AU - Aft, Rebecca

AU - Fuh, Katherine C.

AU - Schwarz, Julie K.

AU - Zevallos, Jose P.

AU - Puram, Sidharth V.

AU - Dipersio, John F.

AU - Belmar, Julie

AU - Held, Jason

AU - Luo, Jingqin

AU - Van Tine, Brian A.

AU - Tipton, Rose

AU - Wu, Yige

AU - Yao, Lijun

AU - Zhou, Daniel Cui

AU - Butterfield, Andrew

AU - Chu, Zhengtao

AU - Fujita, Maihi

AU - Yang, Chieh Hsiang

AU - Cortes-Sanchez, Emilio

AU - Scherer, Sandra

AU - Zhao, Ling

AU - Borovski, Tijana

AU - Chin, Vicki

AU - DiGiovanna, John

AU - Frech, Christian

AU - Grover, Jeffrey

AU - Raphael, Benjamin J.

PY - 2022/12

Y1 - 2022/12

N2 - In this Article the Competing interests statement inadvertently omitted a statement for M.T.L. and L.E.D. The competing financial interests for M.T.L. should have read: ‘M.T.L. is a founder and limited partner in StemMed Ltd. and a manager in StemMed Holdings, its general partner. He is a founder and equity stakeholder in Tvardi Theraeutics Inc. Some PDXs are exclusively licensed to StemMed Ltd. resulting in royalty income to M.T.L.’. The competing financial interests for L.E.D. should have read, ‘L.E.D. is a compensated employee of StemMed Ltd’. The PDF and HTML versions of the Article have been corrected.

AB - In this Article the Competing interests statement inadvertently omitted a statement for M.T.L. and L.E.D. The competing financial interests for M.T.L. should have read: ‘M.T.L. is a founder and limited partner in StemMed Ltd. and a manager in StemMed Holdings, its general partner. He is a founder and equity stakeholder in Tvardi Theraeutics Inc. Some PDXs are exclusively licensed to StemMed Ltd. resulting in royalty income to M.T.L.’. The competing financial interests for L.E.D. should have read, ‘L.E.D. is a compensated employee of StemMed Ltd’. The PDF and HTML versions of the Article have been corrected.

UR - https://www.scopus.com/pages/publications/85122762782

UR - https://www.scopus.com/pages/publications/85122762782#tab=citedBy

U2 - 10.1038/s41467-021-27678-7

DO - 10.1038/s41467-021-27678-7

M3 - Comment/debate

C2 - 34996889

AN - SCOPUS:85122762782

SN - 2041-1723

VL - 13

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 294

ER -

Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this